Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trial.
作者： Sanjay Singh Negi , Anil Agarwal , Adarsh Chaudhary
DOI: 10.1007/S10637-005-3536-2
关键词: Urology 、 Flutamide 、 Placebo-controlled study 、 Surgery 、 Tumor progression 、 Adenocarcinoma 、 Performance status 、 Clinical endpoint 、 Medicine 、 Placebo 、 Survival rate
摘要: Purpose: To evaluate the impact of flutamide on survival patients with unresectable pancreatic cancer. Methods: This single institution, randomized, double-blind, placebo controlled study compared in dose 250 mg three times daily (n = 23) versus histologically proven, previously untreated adenocarcinoma. The primary end point was overall survival; secondary endpoints included 6-month and 1-year rates, performance status response rate. Results: Both groups were well matched regards to demographic, disease related treatment variables. small sample sized study, failed demonstrate a dramatic effect use flutamide. Median 151 days as 136 (p 0.51). rate 39.13% both arms 4.35% 13.04% for group. There no statistically significant difference time deterioration (flutamide 90 68 days, p 0.59) all died result tumor progression. Conclusions: Anti-androgen drug does not appear prolong
springer.com
sci-hub.se 参考文章(25)
Guillermo Robles-Diaz, Vicente Diaz-Sanchez, Juan Pablo Mendez, Araceli Altamirano, Enrique Wolpert, Low serum testosterone/dihydrotestosterone ratio in patients with pancreatic carcinoma. Pancreas. ,vol. 2, pp. 684- 687 ,(1987) , 10.1097/00006676-198711000-00010
Jivesh J. Sharma, Betty Razvillas, C.D. Stephens, Susan G. Hilsenbeck, Ashu Sharma, Mace L. Rothenberg, Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer Investigational New Drugs. ,vol. 15, pp. 361- 364 ,(1997) , 10.1023/A:1005989519350
Brian A. Greenway, Androgen receptor-blocking agents: potential role in pancreatic cancer. Drugs & Aging. ,vol. 17, pp. 161- 163 ,(2000) , 10.2165/00002512-200017030-00001
G. Gonzalez, L. Boix, E. M. Targarona, V. Marco, M. D. Pons, C. Marco, Is exocrine pancreatic cancer a hormone-dependent tumor? A study of the existence of sex hormone receptors in normal and neoplastic pancreas. Hepato-gastroenterology. ,vol. 38, pp. 165- 169 ,(1991)
Å Andrén-Sandberg, Androgen influence on exocrine pancreatic cancer. International Journal of Pancreatology. ,vol. 4, pp. 363- 369 ,(1989) , 10.1007/BF02938472
Courtney M. Townsend, Pomila Singh, James C. Thompson, Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas Gastroenterology. ,vol. 91, pp. 1002- 1006 ,(1986) , 10.1016/0016-5085(86)90707-9
S. Bramhall, J. Buckels, S. J Wigmore, K. C H Fearon, O J. Garden, H S Wasan, B. A Greenway, Effect of flutamide on survival in patients with pancreatic cancer : Study needs to be repeated on a much larger scale BMJ. ,vol. 318, pp. 326- 326 ,(1999) , 10.1136/BMJ.318.7179.326A
OM Taylor, J Teasdale, PN Cowen, MJ McMahon, EA Benson, Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma British Journal of Cancer. ,vol. 66, pp. 503- 506 ,(1992) , 10.1038/BJC.1992.303
I. Fyssas, K. Syrigos, M. Konstandoulakis, S. Papadopoulos, N. Milingos, M. Anapliotou, J. Waxman, B. Golematis, Sex hormone levels in the serum of patients with pancreatic adenocarcinoma. Hormone and Metabolic Research. ,vol. 29, pp. 115- 118 ,(1997) , 10.1055/S-2007-979002
JJ Keating, PJ Johnson, AMG Cochrane, BG Gazzard, N Krasner, PM Smith, PN Trewby, P Wheeler, SP Wilkinson, R Williams, A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. British Journal of Cancer. ,vol. 60, pp. 789- 792 ,(1989) , 10.1038/BJC.1989.361